Therefore, the silencing of mutant KRAS or direct elimination of the KRAS oncoprotein has been regarded as an efficient strategy for the targeted treatment of pancreatic cancers 5, 6, 7. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.